The company hopes to leverage NxGen's assets and relationships in the maternal-fetal medicine space to aid commercialization of its proteomic preterm birth test.
The service business, which the company is calling Aspira IVD, generated $155,000 in revenue from two projects undertaken in the second quarter of 2016.
The company recently completed several clinical studies and closed a CHF 5 million financing round to support commercialization of the proteomic test.
Similar to an earlier study by NIH researchers, the scientists used the platform to detect the p019 protein, which is commonly present in resistant strains.
The company said it plans to use the funds to obtain CE-IVD marking for its lead product, a proteomic test for diagnosing prostate cancer.
In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.
The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.
An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.
In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.